Nusinersen efficacy in 292 children and teenagers from 16 pediatric centers in Poland

Meet the speaker

Prof. Katarzyna Kotulska-Jóźwiak

Katarzyna Kotulska is the Professor and Head of the Department of Neurology at The Children's Memorial Health Institute, Warsaw, Poland. She is also a representative of Poland in the Board of Member State of European Reference Networks.

Dr. Kotulska is certified in neurology and neuropediatrics. She is also a chair of Polish national SMA treatment program.

Dr. Kotulska’s clinical and basic research focuses mainly on rare diseases of the developing nervous system and epileptology. She coordinated the clinical part of the European project EPISTOP ( She is currently a coordinator of two large non-commercial clinical trials, aimed to access the safety and efficacy of rapamycin in preventive treatment in TSC infants (ViRap study) and drug-resistant epilepsy associated with TSC (RaRE-TS study). She is an author of over 160 scientific papers published in peer-reviewed journals and several book chapters.


How nusinersen treatment can be beneficial over time for children and teenagers with SMA regardless of their age, functional status, SMA type, or the number of SMN2 copies.

Hagenacker pubexplainer

Agneta Markstrom presentation

Zac's play day

Marika Pane interview

Thomas Sejersen interview

Agneta Markstrom interview

Mar Tulinius interview

Video Interview Prof. Dr. Hagenacker "New Data on the Treatment of adult SMA with NUS"

Paradigm shift in SMA